1. Flux G, Bardies M, Monsieurs M, Savolainen S, Strand S-E, Lassmann M. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006;16:47-59.
2. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biological bystander effect elicited in vitro by targeted radiopharmaceuticals labelled with α-, β-, and Auger electron-emitting radionuclides. J Nucl Med 2006;47:1007-15.
3. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005;20:47-51.
4. ICRU Report 67. Dose specifications in nuclear medicine. ICRU 2002.
5. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S.